OSA's Digital Library

Optics Express

Optics Express

  • Editor: C. Martijn de Sterke
  • Vol. 17, Iss. 2 — Jan. 19, 2009
  • pp: 509–519

Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient

M. Koetsier, H. L. Lutgers, A. J. Smit, T. P. Links, R. de Vries, R. O. B. Gans, G. Rakhorst, and R. Graaff  »View Author Affiliations

Optics Express, Vol. 17, Issue 2, pp. 509-519 (2009)

View Full Text Article

Enhanced HTML    Acrobat PDF (186 KB)

Browse Journals / Lookup Meetings

Browse by Journal and Year


Lookup Conference Papers

Close Browse Journals / Lookup Meetings

Article Tools



Skin autofluorescence (AF) is becoming an accepted clinical method for assessing the risk of chronic complications in diabetes mellitus (DM). In this study, the role of the excitation wavelength in the recognition of increased risk of diabetes-related chronic complications was investigated. An Excitation Emission Matrix Scanner (EEMS) was used to perform non-invasive measurements in four age-matched groups of patients with type 1 and type 2 DM, with and without chronic complications, as well as in a control group (N=97 in total). AF was calculated for excitation wavelengths in the range 355 – 405 nm. Mean spectra were assessed per group.AF values in both type 1 and type 2 DM patients with complications were increased compared to the control subjects (p < 0.01); this ratio remained practically constant, independent of the excitation wavelength. No emission peaks were distinctive for specific patient groups.We conclude that in these groups, no characteristic fluorophores dictate the use of a specific wavelength or set of wavelengths. The results show the validity of applying a broad excitation wavelength range for risk assessment of chronic complications in diabetes.

© 2009 Optical Society of America

OCIS Codes
(120.3890) Instrumentation, measurement, and metrology : Medical optics instrumentation
(170.1470) Medical optics and biotechnology : Blood or tissue constituent monitoring
(170.4580) Medical optics and biotechnology : Optical diagnostics for medicine
(170.6510) Medical optics and biotechnology : Spectroscopy, tissue diagnostics
(300.6280) Spectroscopy : Spectroscopy, fluorescence and luminescence

ToC Category:
Medical Optics and Biotechnology

Original Manuscript: September 18, 2008
Revised Manuscript: November 25, 2008
Manuscript Accepted: December 17, 2008
Published: January 7, 2009

Virtual Issues
Vol. 4, Iss. 3 Virtual Journal for Biomedical Optics

M. Koetsier, H. Lutgers, A. J. Smit, T. P. Links, R. d. Vries, R. O. Gans, G. Rakhorst, and R. Graaff, "Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient," Opt. Express 17, 509-519 (2009)

Sort:  Author  |  Year  |  Journal  |  Reset  


  1. K. König and H. Schneckenburger, "Laser-induced autofluorescence for medical diagnoses," J. Fluorescence 4, 17-40 (1994). [CrossRef]
  2. N. Ramanujam, Fluorescence spectroscopy in vivo, vol. Biomedical Spectroscopy of Encyclopedia of Analytical Chemistry, (John Wiley & Sons Ltd, Chichester, 2000) pp. 20-56.
  3. M. C. Skala, G. M. Palmer, K. M. Vrotsos, A. Gendron-Fitzpatrick, and N. Ramanujam, "Comparison of a physical model and principal component analysis for the diagnosis of epithelial neoplasias in vivo using diffuse reflectance spectroscopy," Opt. Express 15, 7863-7875 (2007). http://dx.doi.org/10.1364/OE.15.007863. [CrossRef] [PubMed]
  4. R. Na, I. M. Stender, M. Henriksen, and H. C. Wulf, "Autofluorescence of human skin is age-related after correction for skin pigmentation and redness," J. Invest. Dermatol. 116, 536-540 (2001). http://dx.doi.org/10.1046/j.1523-1747.2001.01285.x. [CrossRef] [PubMed]
  5. H. Chang, J. Qu, P. Yuen, J. Sham, D. Kwong, and W. Wei, "Light-induced autofluorescence spectroscopy for detection of nasopharyngeal carcinoma in vivo," Appl. Spectrosc. 56, 1361-1367 (2002). [CrossRef]
  6. L. Brancaleon, A. J. Durkin, J. H. Tu, G. Menaker, J. D. Fallon, and N. Kollias, "In vivo fluorescence spectroscopy of nonmelanoma skin cancer," Photochem. Photobiol. 73, 178-183 (2001). [CrossRef] [PubMed]
  7. D. C. G. de Veld, M. Skurichina, M. J. H. Witjes, R. P. W. Duin, H. J. C. M. Sterenborg, and J. L. N. Roodenburg, "Autofluorescence and diffuse reflectance spectroscopy for oral oncology," Lasers Surg. Med. 36, 356-364 (2005). http://dx.doi.org/10.1002/lsm.20122. [CrossRef] [PubMed]
  8. D. Goujon, M. Zellweger, A. Radu, P. Grosjean, B.-C. Weber, H. van den Bergh, P. Monnier, and G. Wagnières, "In vivo autofluorescence imaging of early cancers in the human tracheobronchial tree with a spectrally optimized system," J. Biomed. Opt. 8, 17-25 (2003). URL http://dx.doi.org/10.1117/1.1528594. [CrossRef] [PubMed]
  9. M. Hammer, E. Nagel, D. Schweitzer, S. Richter, F. Schweitzer, E. Königsdörffer, and J. Strobel, "Spectral separation in ocular fundus autofluorescence images in patients suffering from age-related macular degeneration," Ophthalmologe 101, 1189-1193 (2004). http://dx.doi.org/10.1007/s00347-004-1019-z. [CrossRef] [PubMed]
  10. R. Gillies, G. Zonios, R. R. Anderson, and N. Kollias, "Fluorescence excitation spectroscopy provides information about human skin in vivo," J. Invest. Dermatol. 115, 704-707 (2000). URL http://dx.doi.org/10.1046/j.1523-1747.2000.00091.x. [CrossRef] [PubMed]
  11. L. T. Vo, P. Anikijenko, W. J. McLaren, P. M. Delaney, D. H. Barkla, and R. G. King, "Autofluorescence of skin burns detected by fiber-optic confocal imaging: evidence that cool water treatment limits progressive thermal damage in anesthetized hairless mice," J. Trauma 51, 98-104 (2001). [CrossRef] [PubMed]
  12. J. Sandby-Møller, E. Thieden, P. A. Philipsen, J. Heydenreich, and H. C. Wulf, "Skin autofluorescence as a biological UVR dosimeter," Photodermatol. Photoimmunol. Photomed. 20, 33-40 (2004). [CrossRef] [PubMed]
  13. V. M. Monnier, V. Vishwanath, K. E. Frank, C. A. Elmets, P. Dauchot, and R. R. Kohn, "Relation between complications of type I diabetes mellitus and collagen-linked fluorescence," N. Engl. J. Med. 314, 403-408 (1986). [CrossRef] [PubMed]
  14. A. J. Smit and H. L. Lutgers, "The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation," Curr. Med. Chem. 11, 2767-2784 (2004). [PubMed]
  15. J. W. Baynes and S. R. Thorpe, "Glycoxidation and lipoxidation in atherogenesis," Free Radic. Biol. Med. 28, 1708-1716 (2000). [CrossRef] [PubMed]
  16. M. Brownlee, "Advanced protein glycosylation in diabetes and aging," Annu. Rev. Med. 46, 223-234 (1995). http://dx.doi.org/10.1146/annurev.med.46.1.223. [CrossRef] [PubMed]
  17. T. Miyata, A. Saito, K. Kurokawa, and C. van Ypersele de Strihou, "Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity," Nephrol. Dial. Transplant. 16Suppl 4, 8-11 (2001).
  18. R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt, "Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation," Glycobiology 15(7), 16R-28R (2005). http://dx.doi.org/10.1093/glycob/cwi053. [CrossRef] [PubMed]
  19. J. J. Jager, P. H. N. Oomen, W. J. Sluiter, W. D. Reitsma, A. J. Smit, "Improved reproducibility of the ’largewindow’ method of assessing transcapillary and interstitial fluorescein diffusion in the skin in healthy subjects and in subjects with insulin-dependent diabetes mellitus," Int. J. Microcirc. Clin. Exp. 17, 150-158 (1997). [CrossRef] [PubMed]
  20. T. Abiko, A. Abiko, S. Ishiko, M. Takeda, S. Horiuchi, and A. Yoshida, "Relationship between autofluorescence and advanced glycation end products in diabetic lenses," Exp. Eye Res. 68, 361-366 (1999). http://dx.doi.org/10.1006/exer.1998.0615. [CrossRef] [PubMed]
  21. E. Hull, M. Ediger, A. Unione, E. Deemer, M. Stroman, and J. Baynes, "Noninvasive, optical detection of diabetes: model studies with porcine skin," Opt. Express 12, 4496-4510 (2004). [CrossRef] [PubMed]
  22. N. Kollias, G. Zonios, and G. Stamatas, "Fluorescence spectroscopy of skin," Vib. Spectrosc. 28, 17-23 (2002). [CrossRef]
  23. R. Na, I. M. Stender, and H. C. Wulf, "Can autofluorescence demarcate basal cell carcinoma from normal skin? A comparison with protoporphyrin IX fluorescence," Acta Derm. Venereol. 81, 246-249 (2001). [CrossRef] [PubMed]
  24. R. Meerwaldt, R. Graaff, P. H. N. Oomen, T. P. Links, J. J. Jager, N. L. Alderson, S. R. Thorpe, J. W. Baynes, R. O. B. Gans, and A. J. Smit, "Simple non-invasive assessment of advanced glycation endproduct accumulation," Diabetologia 47, 1324-1330 (2004). http://dx.doi.org/10.1007/s00125-004-1451-2. [CrossRef] [PubMed]
  25. R. Graaff, R. Meerwaldt, H. L. Lutgers, R. Baptist, E. D. de Jong, J. Zijp, T. P. Links, A. J. Smit, and G. Rakhorst, "Instrumentation for the measurement of autofluorescence in the human skin," Proc. SPIE 5692, 111-118 (2005). [CrossRef]
  26. D. J. Mulder, T. V. D. Water, H. L. Lutgers, R. Graaff, R. O. Gans, F. Zijlstra, and A. J. Smit, "Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations," Diabetes Technol. Ther. 8, 523-535 (2006). http://dx.doi.org/10.1089/dia.2006.8.523. [CrossRef] [PubMed]
  27. H. L. Lutgers, R. Graaff, T. P. Links, L. J. Ubink-Veltmaat, H. J. Bilo, R. O. Gans, and A. J. Smit, "Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes," Diabetes Care 29, 2654-2659 (2006). http://dx.doi.org/10.2337/dc05-2173. [CrossRef] [PubMed]
  28. R. Meerwaldt, J. W. L. Hartog, R. Graaff, R. J. Huisman, T. P. Links, N. C. den Hollander, S. R. Thorpe, J. W. Baynes, G. Navis, R. O. B. Gans, and A. J. Smit, "Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients," J. Am. Soc. Nephrol. 16, 3687-3693 (2005). http://dx.doi.org/10.1681/ASN.2005020144. [CrossRef] [PubMed]
  29. D. J. Mulder, P. L. van Haelst, S. Gross, K. de Leeuw, J. Bijzet, R. Graaff, R. O. Gans, F. Zijlstra, A. J. Smit, "Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products," Atherosclerosis 197, 217-223 (2008). http://dx.doi.org/10.1016/j.atherosclerosis.2007.03.027. [CrossRef]
  30. J. Blaauw, A. J. Smit, M. G. van Pampus, J. J. van Doormaal, J. G. Aarnoudse, G. Rakhorst, and R. Graaff, "Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently preeclamptic women," Am. J. Obstet. Gynecol. 195, 717-722 (2006). http://dx.doi.org/10.1016/j.ajog.2006.06.086. [CrossRef] [PubMed]
  31. K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl, "Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus," Rheumatology (Oxford) 46, 1551-1556 (2007). http://dx.doi.org/10.1093/rheumatology/kem215. [CrossRef]
  32. N. den Hollander, D. Mulder, R. Graaff, S. Thorpe, J. Baynes, G. Smit, and A. Smit, "Advanced Glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia," J. Inherit. Metab. Dis. 30, 916-923 (2007). http://dx.doi.org/10.1007/s10545-007-0507-0. [CrossRef]
  33. E. G. Gerrits, H. L. Lutgers, N. Kleefstra, R. Graaff, K. H. Groenier, A. J. Smit, R. O. Gans, and H. J. Bilo, "Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications," Diabetes Care 31, 517-521 (2008). http://dx.doi.org/10.2337/dc07-1755. [CrossRef]
  34. R. Meerwaldt, H. L. Lutgers, T. P. Links, R. Graaff, J. W. Baynes, R. O. B. Gans, and A. J. Smit, "Skin autofluorescence is a strong predictor of cardiac mortality in diabetes," Diabetes Care 30, 107-112 (2007). URL http://dx.doi.org/10.2337/dc06-1391. [CrossRef]
  35. K. A. Destrampe and G. M. Hieftje, "New instrumentation for use in excitation-emission fluorescencepolarization measurements," Appl. Spectrosc. 47, 1548-1554 (1993). [CrossRef]
  36. S. J. Hart and R. D. JiJi, "Light emitting diode excitation emission matrix fluorescence spectroscopy," Analyst 127, 1693-1699 (2002). http://dx.doi.org/10.1039/b207660h. [CrossRef]
  37. J.W. Tunnell, A. E. Desjardins, L. Galindo, I. Georgakoudi, S. A. McGee, J. Mirkovic, M. G. M¨uller, J. Nazemi, F. T. Nguyen, A. Wax, Q. Zhang, R. R. Dasari and M. S. Feld, "Instrumentation for multi-modal spectroscopic diagnosis of epithelial dysplasia," Technol. Cancer Res. Treat. 2, 505-5142003. [PubMed]
  38. A. R. Young, "Chromophores in human skin," Phys. Med. Biol. 42, 789-802 (1997). [CrossRef] [PubMed]
  39. N. Ahmed, P. J. Thornalley, "Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence," Biochem. J. 364, 15-24 (2002). [PubMed]
  40. D. C. G. D. Veld, M. J. H. Witjes, H. J. C. M. Sterenborg, and J. L. N. Roodenburg, "The status of in vivo autofluorescence spectroscopy and imaging for oral oncology," Oral Oncol. 41, 117-131 (2005). http://dx.doi.org/10.1016/j.oraloncology.2004.07.007. [CrossRef] [PubMed]
  41. R. Na, I.-M. Stender, L. Ma, and H. C. Wulf, "Autofluorescence spectrum of skin: component bands and body site variations," Skin Res. Technol. 6, 112-117 (2000). [CrossRef]
  42. V. M. Monnier, O. Bautista, D. Kenny, D. R. Sell, J. Fogarty, W. Dahms, P. A. Cleary, J. Lachin, and S. Genuth, "Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial," Diabetes 48, 870-880 (1999). [CrossRef] [PubMed]
  43. S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and D. C. C. T. S. C. A. S. Group, "Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes," Diabetes 54, 3103-3111 (2005). [CrossRef] [PubMed]

Cited By

Alert me when this paper is cited

OSA is able to provide readers links to articles that cite this paper by participating in CrossRef's Cited-By Linking service. CrossRef includes content from more than 3000 publishers and societies. In addition to listing OSA journal articles that cite this paper, citing articles from other participating publishers will also be listed.

« Previous Article  |  Next Article »

OSA is a member of CrossRef.

CrossCheck Deposited